Regulus Raises $20M from Alnylam, Isis
Regulus Therapeutics said this week that it has received $20 million in Series A preferred equity funding from its two parent companies, Alnylam Pharmaceuticals and Isis Pharmaceuticals.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
An Australian study of personalized medicine has run into problems as it recruits patients.
In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.
The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.
The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.